TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1571340
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (cyclosporine, azathioprine, and prednisolone)
Study: 30277639
Drug: ABVE-PC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVE-PC chemotherapy
Study: 22151619
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine gel
Study: 23093481
Drug: Imdur® Long-Acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imdur® Long-Acting tablet 60 mg
Study: 7970009
Drug: Tizanidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (2 mg to a maximum of 36 mg/d; weeks 2 to 4)
Study: 3620284
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of triprolidine 2.5 mg and dipipanone 8 mg
Study: 26992271
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain control with acetaminophen and opioids (SPC)
Study: 26992271
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain control plus gabapentin (SPC+G)
Study: 23903371
Drug: AMG 416
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 416 (velcalcetide) 10 mg or more
Study: 22171015
Drug: Adjuvanted A/H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted A/H1N1 influenza vaccine
Study: 19381692
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy sleep intervention
Study: 1586710
Drug: Cytoxan (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoxan (120 mg/kg) with total body irradiation (CYTBI)
Study: 1586710
Drug: busulfan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: busulfan (16 mg/kg) (BUSCY)
Study: 31813662
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based chemotherapy (epirubicin)
Study: 30572281
Drug: Platelet-poor plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-poor plasma (PPP) injection
Study: 15532360
Drug: Day 2-Control
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 2-Control group (one retention test administered 24 hr after practice)
Study: 15532360
Drug: Day 1-Day
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1-Day 1 group (two retention tests administered 10 min and 20 min after practice)
Study: 10936742
Drug: Dienogest 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 0.5 mg + Oestradiol valerate 2.0 mg
Study: 10936742
Drug: Dienogest 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2.0 mg + Oestradiol valerate 2.0 mg
Study: 10936742
Drug: Dienogest 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 3.0 mg + Oestradiol valerate 2.0 mg
Study: 10936742
Drug: Dienogest 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 4.0 mg + Oestradiol valerate 2.0 mg
Study: 15725969
Drug: Methylphenidate 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.6 mg/kg
Study: 31326433
Drug: Glepaglutide 10
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glepaglutide 10 mg
Study: 31504303
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet of sofosbuvir and daclatasvir with or without ribavirin
Study: 25033291
Drug: Mefloquine-artesunate (3×
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine-artesunate (3× (100 mg artesunate + 250 mg mefloquine)) + Praziquantel (40 mg/kg)
Study: 18490845
Drug: Kampo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kampo (two capsules containing powdered ginseng 250 mg, powdered oriental bezoar 50 mg, and powdered glycyrrhiza 50 mg)
Study: 15727498
Drug: Naloxone 0.1
Normalized name: naloxone 0.18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.1 mg/70 kg
Study: 15727498
Drug: Drug reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug reinforcement opportunity (fentanyl 1.5 mg/70 kg iv)
Study: 10599652
Drug: 8 fractions
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 fractions of 0 Gy (sham treatment)
Study: 7854516
Drug: High-level vagus
Normalized name: Sus scrofa vagus nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-level vagus nerve stimulation (presumed therapeutic dose)
Study: 7854516
Drug: Low-level vagus
Normalized name: Sus scrofa vagus nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level vagus nerve stimulation (presumed subtherapeutic dose)
Study: 7015799
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release quinidine 0.4 g twice a day
Study: 7015799
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg three times a day
Study: 22192386
Drug: Pedicled buccal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedicled buccal fat pad flap (PBFPF)
Study: 22192386
Drug: Classic buccal
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic buccal sliding flap
Study: 16295337
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of integrative and computerised learning
Study: 9563887
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 450 mg/m2 i.v. for 5 days followed by 15 mg/kg i.v. weekly (arm 1)
Study: 9563887
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) plus levamisole 50 mg p.o. every 8 h for 3 days every 2 weeks (arm 2)
Study: 28002447
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg/mL)
Study: 16374685
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) supplementation at a dosage of 3.1 ± 0.6 mg/kg/day for 9 months
Study: 16374685
Drug: Conventional antifailure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antifailure drugs
Study: 12357147
Drug: 8-mg OROS
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg OROS formulation
Study: 12357147
Drug: 8-mg IR
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg IR formulation
Study: 12357147
Drug: OROS formulation
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS formulation
Study: 2007362
Drug: Clofazimine 100
Normalized name: clofazimine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 100 mg daily (N = 25)
Study: 7124726
Drug: 7.05% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.05% NaCl (osmotic activity equivalent to 15 ml of 23.5% NaCl)
Study: 27898183
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 µg twice daily (EXE)
Study: 17921706
Drug: Breast conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conserving surgery (BCS) plus radiation therapy (RT)
Study: 15067339
Drug: Oral 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-fluorouracil (5-FU) for 1 year in patients receiving surgery and radiotherapy (SR)
Study: 15067339
Drug: Oral 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-fluorouracil (5-FU) for 1 year in patients with pelvic lymph node metastases
Study: 11340355
Drug: Dilazep dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep dihydrochloride (300 mg/day) in normotensive patients (group A)
Study: 11340355
Drug: Dilazep dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep dihydrochloride (300 mg/day) in hypertensive patients (group C)
Study: 7758055
Drug: Piperacillin/tazobactam 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4 g/tazobactam 500 mg, given as intermittent intravenous infusions every 8 hours
Study: 2100659
Drug: Anode Iontophoresis
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anode Iontophoresis using Strontium Chloride Solution (9%)
Study: 2100659
Drug: Anode Iontophoresis
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anode Iontophoresis using Strontium Chloride gel (9%)
Study: 2100659
Drug: Cathode Iontophoresis
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathode Iontophoresis using Sodium Fluoride gel (2%)
Study: 31713940
Drug: 5α-reductase inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5α-reductase inhibitors
Study: 31713940
Drug: 5α-reductase inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5α-reductase inhibitors (at least 3 years use)
Study: 26025794
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib for 3 days followed by oral celecoxib for 4 days
Study: 26025794
Drug: COX-2-specific inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2-specific inhibitors
Study: 15124669
Drug: G-CSF priming
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF priming
Study: 22491395
Drug: Modified Early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT)
Study: 17207028
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg/day for 3 days)
Study: 17207028
Drug: Cefcapene pivoxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefcapene pivoxil hydrochloride (300 mg/day for 3 days)
Study: 3311904
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (control group)
Study: 2636644
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (0.4 g/kg body wt/day of protein and 0.1 g/kg body wt/day of essential amino acids)
Study: 342628
Drug: Monovalent A/New
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent A/New Jersey/76 influenza virus vaccines (two-dose regimens)
Study: 342628
Drug: Split-virus and
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-virus and whole-virus vaccines
Study: 342628
Drug: Two whole-virus
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two whole-virus vaccines
Study: 21522097
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral clonidine)
Study: 20137491
Drug: Octride alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octride alone (octride treatment group)
Study: 16885180
Drug: Thrice-daily tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Thrice-daily tobramycin (divided into three equal doses every 8 hours)
Study: 14713803
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tolterodine ER once daily for 12 weeks
Study: 8538704
Drug: Acellular DTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular DTP vaccines
Study: 9041666
Drug: Acellular vaccine
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccine recipients
Study: 9272346
Drug: Acellular vaccines
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccines
Study: 3253217
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg administered at 21h00
Study: 3253217
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 09h00
Study: 3253217
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 21h00
Study: 3253217
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg administered at 09h00
Study: 31690004
Drug: BBPAS (Brain
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBPAS (Brain Breaks Physical Activity Solutions)
Study: 26840038
Drug: Impaired fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired fasting glucose (100-125 mg/dL)
Study: 9060793
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg once per day) plus placebo; n = 14
Study: 9060793
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg two times per day) plus placebo; n = 18
Study: 9060793
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg once per day) plus Nisoldipine (10 mg two times per day); n = 14
Study: 8342506
Drug: Type IA
Normalized name: MAGNESIUM ALUMINUM SILICATE TYPE IA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type IA antiarrhythmic therapy
Study: 3485054
Drug: PAMBA (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAMBA (1.0 g)
Study: 23402088
Drug: Topical Glyceril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Glyceril trinitrate ointment (0.2%)
Study: 23402088
Drug: Topical Diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Diltiazem gel (2%)
Study: 18697207
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a at 270 microg/week plus ribavirin at 1200 mg/day
Study: 18697207
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a at 180 microg/week plus ribavirin at 1600 mg/day
Study: 10547245
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg OspA vaccine
Study: 9081395
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone 4 mg twice daily as maintenance
Study: 26912506
Drug: Remifentanil (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (i.v. infusion 1-5 µg/kg/h)
Study: 26912506
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose 0.3-0.4 µg/kg followed by i.v. infusion 0.2-1 µg/kg/h)
Study: 22465256
Drug: Weekly, group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly, group-based weight management intervention with individualized calorie intake goal, second counseling session, and weekly group meetings until birth.
Study: 22465256
Drug: Weekly, group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly, group-based weight management intervention.
Study: 8698011
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment comparison
Study: 6370748
Drug: 0.1% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone valerate ointment
Study: 7760093
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg thiopental
Study: 7129299
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg methohexital
Study: 28705573
Drug: Axitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (oral administration for up to 12 weeks)
Study: 14716340
Drug: Immunotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (group B, n=7)
Study: 14716340
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (group A, n=6)
Study: 14716340
Drug: Immunotherapy in
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy in patients relapsing directly into CRel (n=4)
Study: 20456815
Drug: Roasted unsalted
Normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roasted unsalted peanuts (56 g daily for 4 weeks)
Study: 20456815
Drug: Roasted salted
Normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roasted salted peanuts (56 g daily for 4 weeks)
Study: 14698710
Drug: Magnet-activated stimulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnet-activated stimulation during VNS therapy
Study: 8791276
Drug: Interferon-alpha and
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha and high dose interleukin-2
Study: 1365669
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg co-dergocrine mesylate (CDM)
Study: 1365669
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg co-dergocrine mesylate (CDM)
Study: 2857949
Drug: Paracentesis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracentesis plus intravenous albumin infusion
Study: 10509569
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy and ZDV/ddl combination
Study: 1818427
Drug: Nizoral cream
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizoral cream
Study: 31159765
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg/day (3 weeks followed by 1 week rest)
Study: 29176762
Drug: Prenatal lifestyle
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal lifestyle intervention (twice weekly group-exercises and dietary counseling)
Study: 30964416
Drug: Interaction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interaction of H. halys and Fusarium treatments
Study: 22894890
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract (220 mg capsules standardized to 1.2% apigenin)
Study: 18760137
Drug: Antidiabetes regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetes regimens targeting insulin sensitivity
Study: 10634023
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BTA treatment)
Study: 8550117
Drug: Diazepam and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam and Alcohol (combination)
Study: 8550117
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and Propranolol (combination)
Study: 8550117
Drug: Diazepam and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam and Propranolol (combination)
Study: 23281420
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (control group)
Study: 22906730
Drug: Grape extract
Normalized name: grape extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape extract (GE) tablets
Study: 19151458
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg intravenous midazolam
Study: 19151458
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 5mg diazepam + 25 mg promethazine
Study: 11388472
Drug: MBP (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBP (40 mg per day)
Study: 9554821
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate suspension
Study: 1048183
Drug: Trimethoprim-sulfamethoxazole (TMP/SMX)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP/SMX) 10 mg TMP and 50 mg SMX/KG/day orally in two divided doses
Study: 1048183
Drug: Ampicillin 100
Normalized name: ampicillin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 100 mg/kg/day orally in four divided doses
Study: 21497049
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral cataract surgery (2 sessions, 4 to 6 weeks apart)
Study: 15257743
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing + subgingival administration of 10% doxycycline hyclate gel
Study: 15257743
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing + subgingival placebo gel
Study: 7871035
Drug: CP-88,059-1 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-88,059-1 (2 mg to 60 mg)
Study: 21858267
Drug: Herbal drug
Normalized name: herbal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal drug (combination of primrose, gentian root, vervain, elder flowers, and sorrel: Sinupret)
Study: 19117801
Drug: Physician directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician directed product administration
Study: 9145738
Drug: Intravenous ampicillin/sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ampicillin/sulbactam followed by oral amoxicillin/clavulanate for 14-28 days
Study: 19650932
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 mg
Study: 18461016
Drug: Valacyclovir 1
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1 g once daily for 24 weeks
Study: 3046553
Drug: Clozapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (up to 900 mg/d)
Study: 3046553
Drug: Chlorpromazine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (up to 1800 mg/d)
Study: 27738832
Drug: Atorvastatin emulgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin emulgel (2%)